The Latest Breaking News from Kenvue

S&P Dow Jones Indices announced on Monday that Kenvue would join the S&P 500 on Friday. Tuesday’s volume and rising share price suggest that investors feel now is the time to buy its stock.

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.69%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.65%. Stocks on Monday settled mostly higher on a rally...

Morningstar gives wide moat ratings to companies it views with competitive advantages that will last at least 20 years.

The IPO market is expected to thrive in the second half of 2023. Deals are getting larger and less volatile.

Johnson & Johnson rips off Band-Aid and spits out Listerine in a bid to boost margins.

Stock futures build gains, Treasury yields rise, with earnings in focus; Netflix nudges higher as investors eye paid sharing effect on profits; Goldman Sachs gains as bank earnings re-take center stage on Wall Street; Johnson & Johnson earnings on deck with Kenvue IPO, talc bankruptcy in focus and Nvidia shares…

The medical industry, which thrived during the pandemic years, is envisioned to remain buoyed despite the economic headwinds, thanks to the inelastic demand the sector faces. Against this backdrop, we think the strong fundamentals of Johnson and Johnson (JNJ) make it a wise portfolio addition. Read on….

Rising anxieties owing to the likelihood of an impending recession have weighed heavily on the stock market. Given the uncertainties are not likely to ease anytime soon, quality stocks Johnson & Johnson (JNJ) and Pfizer (PFE) might be wise portfolio additions to help you keep money in your pockets. Read…

Johnson & Johnson's consumer health care division, named Kenvue, will have annual sales of around $15 billion.